Society for Biomolecular Sciences to Hold Conference in Asia
News Jun 01, 2010
“A couple of years ago, the SBS board of directors made a strategic decision to expand the society’s reach internationally by bringing high quality science and networking opportunities to a global membership,” said SBS board member and conference committee Chair, John Wang. “As a first step in this strategy, SBS will establish a presence in China, where the pharmaceutical industry has experienced double-digit growth in the last decade, outpacing the country’s overall economic growth and cultivating a large community of pharmaceutical and biotechnological professionals in the process.”
Previously held in North America and Europe, SBS meetings provide a forum for the exchange of knowledge and ideas for scientists who are interested in pre- candidate drug discovery from the pharmaceutical, biotechnology and academic sectors.
In recent years, there has been significant growth within the drug-discovery community in China. Starting with the growth of the CRO sector, many pharmaceutical companies have now established research and development centers in China and there is an emerging and vibrant academic and biotechnology community elsewhere in Asia.
At the first SBS China conference, attendees will hear presentations from leading pharmaceutical companies worldwide and can take advantage of this unique opportunity to network with leaders in the field from Asia, North America and Europe. Additionally, they can explore a vendor exhibition showcasing the latest advances in the applications of novel drug-discovery technologies.
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
XenoGesis and BioAscent Forge Alliance to Offer Enhanced Integrated Drug Discovery ServicesNews
XenoGesis and BioAscent Discovery Limited have announced a collaboration to offer an enhanced range of integrated drug discovery services, including medicinal chemistry, biology and DMPK.READ MORE
BioAscent Establishes Integrated Drug Discovery Services OfferingNews
Dr Phil Jones to join as new CSO to lead company’s extended capabilities in medicinal chemistry and in vitro biosciences.READ MORE